IDH3B

Across TCGA pan-cancer cohorts, IDH3B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IDH3B data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IDH3B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IDH3B expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where IDH3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.470	0.280	.002	17	view →
CCRCC	DFS	Median	III,IV	0.821	1.000	.020	13	view →
GBM	DFS	Median	All	0.863	0.631	.014	5	view →
OV	DFS	Median	All	1.000	0.849	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IDH3B–PDAC (OS)

Open the PDAC breakdown →